Biology and treatment of multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 12, Issue SUPPL. 1, 2006, Pages 81-86

  Tosi, Patrizia ^a   Gamberi, Barbara ^b   Giuliani, Nicola ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Microenvironment; Myeloma; Oncogenes; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN; LENALIDOMIDE; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PNEUMOCOCCUS VACCINE; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SCLEROPROTEIN; STEROID; THALIDOMIDE; THALIDOMIDE DERIVATIVE; ZOLEDRONIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; ENDOTHELIUM; GENE EXPRESSION PROFILING; HUMAN; HYPOGAMMAGLOBULINEMIA; INFECTION; INFLUENZA; LETHARGY; MOLECULAR CLONING; MULTIPLE MYELOMA; ONCOGENE; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PERIPHERAL NEUROPATHY; PLASMA CELL; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; STREPTOCOCCUS INFECTION; STROMA CELL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; B-LYMPHOCYTES; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ONCOGENES;

EID: 29844453760     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.09.008     Document Type: Article

References (37)

1. R.A. Kyle S.V. Rajkumar Multiple myeloma N Engl J Med. 351 2004 1860-1873
2. A. Dispenzieri R.A. Kyle Multiple myeloma: Clinical features and indications for therapy Best Pract Res Clin Haematol. 18 2005 553-568
3. R.A. Kyle M.A. Gertz T.E. Witzig et al. Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc. 78 2003 21-33
4. The International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders a report of the International Myeloma Working Group Br J Haematol. 121 2003 749-757
5. P.R. Greipp J. San Miguel B.G. Durie et al. International staging system for multiple myeloma J Clin Oncol. 23 2005 3412-3420
6. S. Soverini M. Cavo C. Cellini et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 2003 1588-1594
7. R. Fonseca B. Barlogie R. Bataille et al. Genetics and cytogenetics of multiple myeloma: A workshop report Cancer Res. 64 2004 1546-1558
8. F. Zhan J. Hardin B. Kordsmeier et al. Global gene expression profiling in multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells Blood 99 2002 1745-1757
9. J.D. Shaughnessy B. Barlogie Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling Immunol Rev. 194 2003 140-163
10. B. Barlogie J. Shaughnessy G. Tricot et al. Treatment of multiple myeloma Blood 103 2004 20-32
11. J.S. Damiano A.E. Cress L.A. Hazlehurst et al. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1999 1658-1667
12. B. Dankbar T. Pedro R. Leo et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 95 2000 2630-2636
13. A. Vacca D. Ribatti M. Presta et al. Bone marrow neovascularization, plasma cell angiogenetic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064-3073
14. W.T. Bellamy L. Richter Y. Frutiger et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies Blood 59 1999 728-733
15. N. Giuliani R. Bataille C. Mancini et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 98 2001 3527-3533
16. O. Sezer I. Zavrski A. Kuhne et al. RANK ligand and osteoprotegerin in myeloma bone disease Blood 101 2003 2094-2098
17. E. Tian F. Zhan R. Walker et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med. 349 2003 2483-2494
18. M. Abe K. Hiura J. Wilde Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion Blood 104 2004 2484-2491
19. M. Attal J.L. Harousseau A.M. Stoppa et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med. 335 1996 91-97
20. J.A. Child G.J. Morgan F.E. Davies et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med. 348 2003 1875-1883
21. M. Attal J.L. Harousseau T. Facon et al. Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med. 349 2003 2495-2502
22. M. Cavo P. Tosi E. Zamagni et al. The "Bologna 96" clinical trial of single vs double autotransplants for previously untreated multiple myeloma patients [abstract] Blood 100 suppl 1 2002 669
23. S. Singhal J. Metha R. Desikan et al. Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med. 341 1999 1565-1571
24. M. Cavo E. Zamagni P. Tosi et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 2005 35-39
25. S.V. Rajkumar E. Blood D.H. Vesole et al. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract] Blood 104 2004 63
26. A. Badros B. Barlogie E. Siegel et al. Results of autologous stem cell transplants in multiple myeloma patients with renal failure Br J Haematol. 114 2001 822-829
27. P.G. Richardson S. Jagannath M.A. Hussein et al. A multicenter single-arm open-label study to evaluate the safety and efficacy of single-agent lenalidomide in subjects with relapsed and refractory multiple myeloma [abstract] Haematologica suppl 1 2005 154
28. P.G. Richardson B. Barlogie J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med. 348 2003 2609-2617
29. P.G. Richardson P. Sonneveld M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med. 352 2005 2487-2498
30. W.I. Bensinger C.D. Buckner C. Anasetti et al. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome Blood 88 1996 2787-2793
31. M. Cavo G. Bandini M. Benni et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma Bone Marrow Transplant. 22 1998 27-32
32. B. Bjorkstrand P. Ljungman H. Svensson et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 88 1996 4711-4718
33. G. Gahrton H. Svensson M. Cavo et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres Br J Haematol. 113 2001 209-216
34. M. Cavo C. Terragna G. Martinelli et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma Blood 96 2000 355-357
35. G. Martinelli C. Terragna E. Zamagni et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cell for multiple myeloma J Clin Oncol. 18 2000 2273-2281
36. C. Crawley M. Lalancette R. Szydlo et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT Blood 105 2005 4532-4539
37. G. Barosi M. Boccadoro M. Cavo et al. Management of multiple myeloma and related disorders: Guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) Haematologica 89 2004 717-741